Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity

Cancer Immunol Res. 2024 Nov 4;12(11):1525-1541. doi: 10.1158/2326-6066.CIR-24-0463.

Abstract

Progressive decline of the adaptive immune system with increasing age coincides with a sharp increase in cancer incidence. In this study, we set out to understand whether deficits in antitumor immunity with advanced age promote tumor progression and/or drive resistance to immunotherapy. We found that multiple syngeneic cancers grew more rapidly in aged versus young adult mice, driven by dysfunctional CD8+ T-cell responses. By systematically mapping immune cell profiles within tumors, we identified loss of tumor antigen-specific CD8+ T cells as a primary feature accelerating the growth of tumors in aged mice and driving resistance to immunotherapy. When antigen-specific T cells from young adult mice were administered to aged mice, tumor outgrowth was delayed and the aged animals became sensitive to PD-1 blockade. These studies reveal how age-associated CD8+ T-cell dysfunction may license tumorigenesis in elderly patients and have important implications for the use of aged mice as preclinical models of aging and cancer.

MeSH terms

  • Age Factors
  • Aging / immunology
  • Animals
  • CD8-Positive T-Lymphocytes* / immunology
  • Cell Line, Tumor
  • Disease Models, Animal
  • Female
  • Humans
  • Immunotherapy / methods
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms / immunology